{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:36:41Z","timestamp":1787582201572,"version":"build-2736575974"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007069","name":"Universit\u00e0 della Calabria","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007069","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Updates Surg"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Esophageal cancer (EC) remains a highly lethal malignancy, characterized by late diagnosis, early systemic dissemination, and high recurrence rates. Conventional diagnostic and surveillance strategies have limited sensitivity for early disease detection and minimal residual disease. Liquid biopsy technologies have emerged as promising minimally invasive tools for diagnosis, prognostication, and longitudinal monitoring. This scoping review summarizes current evidence on the clinical utilization of liquid biopsies in esophageal squamous cell and adenocarcinoma. PubMed, EMBASE and Cochrane Library were queried. Inclusion criteria encompassed studies investigating the use of liquid biopsy for EC diagnosis, treatment response evaluation, and prognosis definition. A total of 73 studies reported the role of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), or microRNAs (miRNA). The majority (59%) focused on ctDNA while CTC and miRNA were assessed in 12 and 14 studies, respectively. The reported pooled diagnostic sensitivity and specificity was 71% and 98.6%, respectively, with superior performance in advanced stages (III-IV). Serial ctDNA measurements during neoadjuvant therapy have been reported useful for assessing tumor burden reduction. Additionally, comprehensive ctDNA profiling proved valuable for analysis of tumor heterogeneity and actionable genetic alterations suitable for targeted treatment therapies. Elevated preoperative ctDNA levels correlated with an increased risk of nodal metastasis and postoperative cancer recurrence. ctDNA was also identified as a useful prognostic marker, demonstrating sensitivity and specificity of 49% and 95%, respectively, for survival prediction. Despite limitations related to the various methodologies employed and the lack of laboratory standardization, liquid biopsy constitutes a promising frontier in the surgical management of EC, offering minimally invasive, real-time tool for assessing tumor genetics, genomic heterogeneity, and dynamics of tumor progression. It might enhance early diagnosis, inform neoadjuvant treatment response, and enable postoperative surveillance for residual or recurrent cancer.<\/jats:p>","DOI":"10.1007\/s13304-026-02814-4","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:55:42Z","timestamp":1787579742000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Role of liquid biopsy in the multimodal assessment and treatment of esophageal cancer: a surgical perspective"],"prefix":"10.1007","author":[{"given":"Alberto","family":"Aiolfi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Bona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Rausa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimira","family":"Tich\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Biondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juana","family":"Riitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4880-1670","authenticated-orcid":false,"given":"Luigi","family":"Bonavina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"issue":"3","key":"2814_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"2814_CR2","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(19)30456-5","volume":"20","author":"M Arnold","year":"2019","unstructured":"Arnold M, Rutherford MJ, Bardot A, et al. (2019) Progress in cancer survival, mortality, and incidence in seven high-income countries 1995\u20132014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol 20(11):1493\u20131505. https:\/\/doi.org\/10.1016\/S1470-2045(19)30456-5","journal-title":"Lancet Oncol"},{"issue":"2","key":"2814_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.14740\/wjon1254","volume":"11","author":"EO Then","year":"2020","unstructured":"Then EO, Lopez M, Saleem S, Gayam V, Sunkara T, Culliford A, Gaduputi V (2020) Esophageal cancer: an updated surveillance epidemiology and end results database analysis. World J Oncol 11(2):55\u201364. https:\/\/doi.org\/10.14740\/wjon1254","journal-title":"World J Oncol"},{"issue":"9","key":"2814_CR4","doi-asserted-by":"publisher","first-page":"5564","DOI":"10.1245\/s10434-023-13670-6","volume":"30","author":"A Aiolfi","year":"2023","unstructured":"Aiolfi A, Griffiths EA, Sozzi A, Manara M, Bonitta G, Bonavina L, Bona D (2023) Effect of anastomotic leak on long-term survival after esophagectomy: multivariate meta-analysis and restricted mean survival times examination. Ann Surg Oncol 30(9):5564\u20135572. https:\/\/doi.org\/10.1245\/s10434-023-13670-6","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"2814_CR5","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.surg.2021.08.029","volume":"171","author":"D Bona","year":"2022","unstructured":"Bona D, Lombardo F, Matsushima K, Cavalli M, Lastraioli C, Bonitta G, Cirri S, Danelli P, Aiolfi A (2022) Three-field versus two-field lymphadenectomy for esophageal squamous cell carcinoma: a long-term survival meta-analysis. Surgery 171(4):940\u2013947. https:\/\/doi.org\/10.1016\/j.surg.2021.08.029","journal-title":"Surgery"},{"issue":"10","key":"2814_CR6","doi-asserted-by":"publisher","first-page":"7891","DOI":"10.1245\/s10434-025-17823-7","volume":"32","author":"A Aiolfi","year":"2025","unstructured":"Aiolfi A, Bona D, De Bernardi S, Bonitta G, Wang Q, Biondi A, Bonavina L (2025) Impact of centralizing esophageal cancer surgery at high-volume centers on long-term survival: individual patient data meta-analysis. Ann Surg Oncol 32(10):7891\u20137900. https:\/\/doi.org\/10.1245\/s10434-025-17823-7","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"2814_CR7","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","volume":"16","author":"J Shapiro","year":"2015","unstructured":"Shapiro J, van Lanschot JJB, Hulshof MCCM, et al (2015) Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 16(9):1090\u20131098","journal-title":"Lancet Oncol"},{"issue":"5","key":"2814_CR8","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1097\/SLA.0000000000005617","volume":"276","author":"NE Donlon","year":"2022","unstructured":"Donlon NE, Moran B, Kamilli A et al (2022) CROSS versus FLOT regimens in esophageal and esophagogastric junction adenocarcinoma: a propensity-matched comparison. Ann Surg 276(5):792\u2013798. https:\/\/doi.org\/10.1097\/SLA.0000000000005617","journal-title":"Ann Surg"},{"issue":"4","key":"2814_CR9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa2409408","volume":"392","author":"J Hoeppner","year":"2025","unstructured":"Hoeppner J, Brunner T, Schmoor C et al (2025) Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer. N Engl J Med 392(4):323\u2013335. https:\/\/doi.org\/10.1056\/NEJMoa2409408","journal-title":"N Engl J Med"},{"issue":"11","key":"2814_CR10","doi-asserted-by":"publisher","first-page":"8503","DOI":"10.1097\/JS9.0000000000002985","volume":"111","author":"A Aiolfi","year":"2025","unstructured":"Aiolfi A, Cammarata F, Bonitta G, Bona D, Bonavina L (2025) Open, hybrid, minimally invasive, and robotic-assisted transthoracic esophagectomy for cancer: a network meta-analysis of randomized trials. Int J Surg 111(11):8503\u20138514. https:\/\/doi.org\/10.1097\/JS9.0000000000002985","journal-title":"Int J Surg"},{"key":"2814_CR11","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"S-E Al-Batran","year":"2019","unstructured":"Al-Batran S-E, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp H-G, Mayer F, Haag GM, Luley K et al (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet 393:1948\u20131957. https:\/\/doi.org\/10.1016\/S0140-6736(18)32557-1","journal-title":"Lancet"},{"key":"2814_CR12","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P van Hagen","year":"2012","unstructured":"van Hagen P, Hulshof MCCM, van Lanschot JJB, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BPL, Richel DJ, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074\u20132084. https:\/\/doi.org\/10.1056\/NEJMoa1112088","journal-title":"N Engl J Med"},{"key":"2814_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ejca.2017.04.027","volume":"81","author":"M Stahl","year":"2017","unstructured":"Stahl M, Walz MK, Riera-Knorrenschild J, Stuschke M, Sandermann A, Bitzer M, Wilke H, Budach W (2017) Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): long-term results of a controlled randomised trial. Eur J Cancer 81:183\u2013190. https:\/\/doi.org\/10.1016\/j.ejca.2017.04.027","journal-title":"Eur J Cancer"},{"key":"2814_CR14","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S2468-1253(23)00243-1","volume":"8","author":"JV Reynolds","year":"2023","unstructured":"Reynolds JV, Preston SR, O\u2019Neill B, Lowery MA, Baeksgaard L, Crosby T, Cunningham M, Cuffe S, Griffiths GO, Parker I et al (2023) Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial. Lancet Gastroenterol Hepatol 8:1015\u20131027. https:\/\/doi.org\/10.1016\/S2468-1253(23)00243-1","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2814_CR15","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","volume":"384","author":"RJ Kelly","year":"2021","unstructured":"Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Li\u00e8vre A et al (2021) Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 384:1191\u20131203. https:\/\/doi.org\/10.1056\/NEJMoa2032125","journal-title":"N Engl J Med"},{"key":"2814_CR16","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1200\/JCO.2024.42.3_suppl.326","volume":"42","author":"T Yoshii","year":"2024","unstructured":"Yoshii T, Yamamoto S, Kato K, Daiko H, Hara H, Kojima T, Abe T, Tsubosa Y, Kawakubo H, Fujita T et al (2024) FRONTiER: a feasibility trial of nivolumab with neoadjuvant CF or DCF, FLOT therapy for locally advanced esophageal carcinoma (JCOG1804E)\u2014primary safety and short-term efficacy results for cohort E. J Clin Oncol 42:326. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.326","journal-title":"J Clin Oncol"},{"issue":"2","key":"2814_CR17","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3390\/cancers17020196","volume":"17","author":"Y Hoshi","year":"2025","unstructured":"Hoshi Y, Matsuda S, Takeuchi M, Kawakubo H, Kitagawa Y (2025) Liquid biopsy and multidisciplinary treatment for esophageal cancer. Cancers (Basel) 17(2):196. https:\/\/doi.org\/10.3390\/cancers17020196","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2814_CR18","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","volume":"9","author":"L Ma","year":"2024","unstructured":"Ma L, Guo H, Zhao Y, Liu Z, Wang C, Bu J, Sun T, Wei J (2024) Liquid biopsy in cancer current: status, challenges and future prospects. Signal Transduct Target Ther 9(1):336. https:\/\/doi.org\/10.1038\/s41392-024-02021-w","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2814_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/cac2.12118","volume":"41","author":"Z Yuan","year":"2021","unstructured":"Yuan Z, Wang X, Geng X, Li Y, Mu J, Tan F, Xue Q, Gao S, He J (2021) Liquid biopsy for esophageal cancer: Is detection of circulating cell-free DNA as a biomarker feasible? Cancer Commun (Lond) 41(1):3\u201315. https:\/\/doi.org\/10.1002\/cac2.12118","journal-title":"Cancer Commun (Lond)"},{"issue":"2","key":"2814_CR20","doi-asserted-by":"publisher","first-page":"doab046","DOI":"10.1093\/dote\/doab046","volume":"35","author":"S Chidambaram","year":"2022","unstructured":"Chidambaram S, Markar SR (2022) Clinical utility and applicability of circulating tumor DNA testing in esophageal cancer: a systematic review and meta-analysis. Dis Esophagus 35(2):doab046. https:\/\/doi.org\/10.1093\/dote\/doab046","journal-title":"Dis Esophagus"},{"key":"2814_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1364557032000119616","volume":"8","author":"H Arksey","year":"2005","unstructured":"Arksey H, O\u2019Malley L (2005) Scoping studies: towards a methodological framework. Int J Soc Res Methodol Theory Pract 8:19\u201332. https:\/\/doi.org\/10.1080\/1364557032000119616","journal-title":"Int J Soc Res Methodol Theory Pract"},{"key":"2814_CR22","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tun\u00e7alp \u00d6, Straus SE (2018) PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 169:467. https:\/\/doi.org\/10.7326\/M18-0850","journal-title":"Ann Intern Med"},{"key":"2814_CR23","doi-asserted-by":"publisher","first-page":"1622984","DOI":"10.3389\/fonc.2025.1622984","volume":"15","author":"D Tai","year":"2025","unstructured":"Tai D, Latif K, Shah P, Park D, Crook C, Guzman S, Brar G, Li D, Castillo D (2025) Multi-analyte liquid biopsy approaches for early detection of esophageal cancer: the expanding role of ctDNA. Front Oncol 15:1622984. https:\/\/doi.org\/10.3389\/fonc.2025.1622984","journal-title":"Front Oncol"},{"issue":"3","key":"2814_CR24","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s43018-020-0043-5","volume":"1","author":"DW Cescon","year":"2020","unstructured":"Cescon DW, Bratman SV, Chan SM, Siu LL (2020) Circulating tumor DNA and liquid biopsy in oncology. Nat Cancer 1(3):276\u2013290. https:\/\/doi.org\/10.1038\/s43018-020-0043-5","journal-title":"Nat Cancer"},{"issue":"2","key":"2814_CR25","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","volume":"20","author":"E Heitzer","year":"2019","unstructured":"Heitzer E, Haque IS, Roberts CES, Speicher MR (2019) Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet 20(2):71\u201388. https:\/\/doi.org\/10.1038\/s41576-018-0071-5","journal-title":"Nat Rev Genet"},{"issue":"8","key":"2814_CR26","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1080\/15384047.2019.1598759","volume":"20","author":"A Kustanovich","year":"2019","unstructured":"Kustanovich A, Schwartz R, Peretz T, Grinshpun A (2019) Life and death of circulating cell-free DNA. Cancer Biol Ther 20(8):1057\u20131067. https:\/\/doi.org\/10.1080\/15384047.2019.1598759","journal-title":"Cancer Biol Ther"},{"issue":"7","key":"2814_CR27","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.1097\/JS9.0000000000001373","volume":"110","author":"H Zhang","year":"2024","unstructured":"Zhang H, Jin T, Peng Y, Luan S, Li X, Xiao X, Yuan Y (2024) Association between plasma circulating tumor DNA and the prognosis of esophageal cancer patients: a meta-analysis. Int J Surg 110(7):4370\u20134381. https:\/\/doi.org\/10.1097\/JS9.0000000000001373","journal-title":"Int J Surg"},{"issue":"9","key":"2814_CR28","doi-asserted-by":"publisher","first-page":"e45784","DOI":"10.7759\/cureus.45784","volume":"15","author":"P Bittla","year":"2023","unstructured":"Bittla P, Kaur S, Sojitra V, Zahra A, Hutchinson J, Folawemi O, Khan S (2023) Exploring circulating tumor DNA (CtDNA) and its role in early detection of cancer: a systematic review. Cureus 15(9):e45784. https:\/\/doi.org\/10.7759\/cureus.45784","journal-title":"Cureus"},{"key":"2814_CR29","doi-asserted-by":"publisher","first-page":"1354195","DOI":"10.3389\/fgene.2024.1354195","volume":"15","author":"Y Xu","year":"2024","unstructured":"Xu Y, Wang Z, Pei B, Wang J, Xue Y, Zhao G (2024) DNA methylation markers in esophageal cancer. Front Genet 15:1354195. https:\/\/doi.org\/10.3389\/fgene.2024.1354195","journal-title":"Front Genet"},{"key":"2814_CR30","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","volume":"15","author":"M Nikanjam","year":"2022","unstructured":"Nikanjam M, Kato S, Kurzrock R (2022) Liquid biopsy: current technology and clinical applications. J Hematol Oncol 15:131. https:\/\/doi.org\/10.1186\/s13045-022-01351-y","journal-title":"J Hematol Oncol"},{"key":"2814_CR31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.20892\/j.issn.2095-3941.2018.0055","volume":"16","author":"D Qin","year":"2019","unstructured":"Qin D (2019) Next-generation sequencing and its clinical application. Cancer Biol Med 16:4\u201310. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2018.0055","journal-title":"Cancer Biol Med"},{"issue":"224","key":"2814_CR32","doi-asserted-by":"publisher","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda C, Sausen M, Leary RJ et al (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6(224):224ra24. https:\/\/doi.org\/10.1126\/scitranslmed.3007094","journal-title":"Sci Transl Med"},{"issue":"5","key":"2814_CR33","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3390\/cancers11050736","volume":"11","author":"M Davidson","year":"2019","unstructured":"Davidson M, Barber LJ, Woolston A et al (2019) Detecting and tracking circulating tumour DNA copy number profiles during first line chemotherapy in oesophagogastric adenocarcinoma. Cancers (Basel) 11(5):736. https:\/\/doi.org\/10.3390\/cancers11050736","journal-title":"Cancers (Basel)"},{"key":"2814_CR34","doi-asserted-by":"crossref","unstructured":"Jia R, Zhao CH, Li PS et al (2021) Post-radiation circulating tumor DNA as a prognostic factor in locally advanced esophageal squamous cell carcinoma. Oncol Lett 21(1):68","DOI":"10.3892\/ol.2020.12329"},{"issue":"8","key":"2814_CR35","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1158\/1078-0432.CCR-17-3103","volume":"24","author":"AB Schrock","year":"2018","unstructured":"Schrock AB, Pavlick D, Klempner SJ et al (2018) Hybrid capture\u2013based genomic profiling of circulating tumor DNA from patients with advanced cancers of the gastrointestinal tract or anus. Clin Cancer Res 24(8):1881\u20131890. https:\/\/doi.org\/10.1158\/1078.","journal-title":"Clin Cancer Res"},{"issue":"38","key":"2814_CR36","doi-asserted-by":"publisher","first-page":"62280","DOI":"10.18632\/oncotarget.11409","volume":"7","author":"M Ueda","year":"2016","unstructured":"Ueda M, Iguchi T, Masuda T et al (2016) Somatic mutations in plasma cell-free DNA are diagnostic markers for esophageal squamous cell carcinoma recurrence. Oncotarget 7(38):62280\u201362291. https:\/\/doi.org\/10.18632\/oncotarget.11409","journal-title":"Oncotarget"},{"issue":"23","key":"2814_CR37","doi-asserted-by":"publisher","first-page":"7098","DOI":"10.1158\/1078-0432.CCR-19-1704","volume":"25","author":"SB Maron","year":"2019","unstructured":"Maron SB, Chase LM, Lomnicki S et al (2019) Circulating tumor DNA sequencing analysis of gastroesophageal adenocarcinoma. Clin Cancer Res 25(23):7098\u20137112. https:\/\/doi.org\/10.1158\/1078.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2814_CR38","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1158\/1535-7163.MCT-17-0360","volume":"17","author":"P Riviere","year":"2018","unstructured":"Riviere P, Fanta PT, Ikeda S, Baumgartner J, Heestand GM, Kurzrock R (2018) The mutational landscape of gastrointestinal malignancies as reflected by circulating tumor DNA. Mol Cancer Ther 17(1):297\u2013305. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0360","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"2814_CR39","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1007\/s10620-013-3005-2","volume":"59","author":"S Komatsu","year":"2014","unstructured":"Komatsu S, Ichikawa D, Hirajima S et al (2014) Clinical impact of predicting CCND1 amplification using plasma DNA in superficial esophageal squamous cell carcinoma. Dig Dis Sci 59(6):1152\u20131159. https:\/\/doi.org\/10.1007\/s10620-013-3005-2","journal-title":"Dig Dis Sci"},{"issue":"3","key":"2814_CR40","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1053\/j.gastro.2019.10.039","volume":"158","author":"TD Azad","year":"2020","unstructured":"Azad TD, Chaudhuri AA, Fang P et al (2020) Circulating tumor DNA analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal cancer. Gastroenterology 158(3):494\u2013505e6. https:\/\/doi.org\/10.1053\/j.gastro.2019.10.039","journal-title":"Gastroenterology"},{"issue":"4","key":"2814_CR41","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.bbrc.2016.02.011","volume":"471","author":"H Luo","year":"2016","unstructured":"Luo H, Li H, Hu Z et al (2016) Noninvasive diagnosis and monitoring of mutations by deep sequencing of circulating tumor DNA in esophageal squamous cell carcinoma. Biochem Biophys Res Commun 471(4):596\u2013602. https:\/\/doi.org\/10.1016\/j.bbrc.2016.02.011","journal-title":"Biochem Biophys Res Commun"},{"key":"2814_CR42","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.athoracsur.2019.04.004","volume":"108","author":"M Egyud","year":"2019","unstructured":"Egyud M, Tejani M, Pennathur A, Luketich J, Sridhar P, Yamada E et al (2019) Detection of circulating tumor DNA in plasma: a potential biomarker for esophageal adenocarcinoma. Ann Thorac Surg 108:343\u2013349. https:\/\/doi.org\/10.1016\/j.athoracsur.2019.04.004","journal-title":"Ann Thorac Surg"},{"key":"2814_CR43","doi-asserted-by":"publisher","first-page":"e934106","DOI":"10.12659\/MSM.934106","volume":"28","author":"J Min","year":"2022","unstructured":"Min J, Zhou H, Jiang S, Yu H (2022) A review of circulating tumor DNA in the diagnosis and monitoring of esophageal cancer. Med Sci Monit 28:e934106. https:\/\/doi.org\/10.12659\/MSM.934106","journal-title":"Med Sci Monit"},{"key":"2814_CR44","doi-asserted-by":"publisher","first-page":"7396","DOI":"10.1158\/1078-0432.CCR-19-0740","volume":"25","author":"Y Qin","year":"2019","unstructured":"Qin Y, Wu CW, Taylor WR, Sawas T, Burger KN, Mahoney DW et al (2019) Discovery, validation, and application of novel methylated DNA markers for detection of esophageal cancer in plasma. Clin Cancer Res 25:7396\u20137404. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0740","journal-title":"Clin Cancer Res"},{"key":"2814_CR45","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12916-021-02109-y","volume":"19","author":"G Qiao","year":"2021","unstructured":"Qiao G, Zhuang W, Dong B, Li C, Xu J, Wang G et al (2021) Discovery and validation of methylation signatures in circulating cell-free DNA for early detection of esophageal cancer: a case-control study. BMC Med 19:243. https:\/\/doi.org\/10.1186\/s12916-021-02109-y","journal-title":"BMC Med"},{"key":"2814_CR46","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","volume":"31","author":"MC Liu","year":"2020","unstructured":"Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV, Consortium C (2020) Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol 31:745\u2013759. https:\/\/doi.org\/10.1016\/j.annonc.2020.02.011","journal-title":"Ann Oncol"},{"key":"2814_CR47","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/s41419-023-06329-3","volume":"14","author":"D Lu","year":"2023","unstructured":"Lu D, Wu X, Wu W, Wu S, Li H, Zhang Y et al (2023) Plasma cell-free DNA 5-hydroxymethylcytosine and whole-genome sequencing signatures for early detection of esophageal cancer. Cell Death Dis 14:843. https:\/\/doi.org\/10.1038\/s41419-023-06329-3","journal-title":"Cell Death Dis"},{"key":"2814_CR48","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","volume":"5","author":"T Reinert","year":"2019","unstructured":"Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H, Knudsen M, Nordentoft I, Wu HT, Tin AS et al (2019) Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol 5:1124\u20131131","journal-title":"JAMA Oncol"},{"key":"2814_CR49","doi-asserted-by":"publisher","first-page":"e2100298","DOI":"10.1200\/PO.21.00298","volume":"6","author":"PM Kasi","year":"2022","unstructured":"Kasi PM (2022) Tumor-informed versus plasma-only liquid biopsy assay in a patient with multiple primary malignancies. JCO Precis Oncol 6:e2100298. https:\/\/doi.org\/10.1200\/PO.21.00298","journal-title":"JCO Precis Oncol"},{"key":"2814_CR50","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-026-04495-2","author":"HM Ahmed","year":"2026","unstructured":"Ahmed HM, Al-Hussainy AF, Mustafa WW, Jyothi SR, Nayak PP, Janney JB, Singh G, Sinha A, Sameer HN, Salih RM, Adil M, Salajegheh P (2026) Circulating tumor DNA dynamics predict pathological response and guide therapy personalization in the neoadjuvant setting. Discov Oncol. https:\/\/doi.org\/10.1007\/s12672-026-04495-2","journal-title":"Discov Oncol"},{"issue":"6","key":"2814_CR51","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.3390\/cancers12061352","volume":"12","author":"JMY Ko","year":"2020","unstructured":"Ko JMY, Ng HY, Lam KO, Chiu KWH, Kwong DLW, Lo AWI, Wong JC, Lin RCW, Fong HCH, Li JYK, Dai W, Law S, Lung ML (2020) Liquid biopsy serial monitoring of treatment responses and relapse in advanced esophageal squamous cell carcinoma. Cancers (Basel) 12(6):1352. https:\/\/doi.org\/10.3390\/cancers12061352","journal-title":"Cancers (Basel)"},{"key":"2814_CR52","doi-asserted-by":"publisher","unstructured":"Hong TH, Jeong JG, Park SY, Park BJ, Kyung D, Kim HP, Zhu J, Yang YH, Kim HE, Lee CY, Lee JG, Jeon YJ, Lee J, Cho JH, Choi YS, Shim YM, Lee SH, Kim DJ, Kim HK (2026) Preoperative circulating tumor DNA detection and risk stratification in esophageal squamous cell carcinoma. JAMA Surg e256755. https:\/\/doi.org\/10.1001\/jamasurg.2025.6755","DOI":"10.1001\/jamasurg.2025.6755"},{"issue":"9","key":"2814_CR53","doi-asserted-by":"publisher","first-page":"102334","DOI":"10.1016\/j.xcrm.2025.102334","volume":"6","author":"Z Liu","year":"2025","unstructured":"Liu Z, Wang G, Yang Y, Su Y, Zhang H, Liu J, Cui P, Fan X, Yang J, Zhang Z, Gao X, Chao Y, Mostert B, van Lanschot JJB, Wijnhoven BPL, Law S, Li C, Cai S, Li Z (2025) ctDNA detects residual disease after neoadjuvant chemoradiotherapy and guides adjuvant therapy in esophageal squamous cell carcinoma. Cell Rep Med 6(9):102334. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102334","journal-title":"Cell Rep Med"},{"key":"2814_CR54","doi-asserted-by":"publisher","first-page":"e2200420","DOI":"10.1200\/PO.22.00420","volume":"6","author":"BM Huffman","year":"2022","unstructured":"Huffman BM, Aushev VN, Budde GL, Chao J, Dayyani F, Hanna D, Botta GP, Catenacci DVT, Maron SB, Krinshpun S, Sharma S, George GV, Malhotra M, Jurdi A, Moshkevich S, Aleshin A, Kasi PM, Klempner SJ (2022) Analysis of circulating tumor DNA to predict risk of recurrence in patients with esophageal and gastric cancers. JCO Precis Oncol 6:e2200420. https:\/\/doi.org\/10.1200\/PO.22.00420","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"2814_CR55","doi-asserted-by":"publisher","first-page":"109625","DOI":"10.1016\/j.ejso.2025.109625","volume":"51","author":"R Kobayashi","year":"2025","unstructured":"Kobayashi R, Matsuda S, Nakamura K, Kawakubo H, Ho K, Morimoto Y, Hisaoka K, Hoshi Y, Takeuchi M, Fukuda K, Okui J, Nishihara H, Kitagawa Y (2025) Clinical value of preoperative circulating tumor DNA before surgery in patients with esophageal squamous cell carcinoma. Eur J Surg Oncol 51(5):109625. https:\/\/doi.org\/10.1016\/j.ejso.2025.109625","journal-title":"Eur J Surg Oncol"},{"key":"2814_CR56","doi-asserted-by":"publisher","first-page":"616209","DOI":"10.3389\/fonc.2021.616209","volume":"11","author":"T Liu","year":"2021","unstructured":"Liu T, Yao Q, Jin H (2021) Plasma circulating tumor DNA sequencing predicts minimal residual disease in resectable esophageal squamous cell carcinoma. Front Oncol 11:616209","journal-title":"Front Oncol"},{"key":"2814_CR57","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1097\/SLA.0000000000005177","volume":"276","author":"CS Cabalag","year":"2022","unstructured":"Cabalag CS, Yates M, Corrales MB et al (2022) Potential clinical utility of a targeted circulating tumor DNA assay in esophageal adenocarcinoma. Ann Surg 276:e120\u2013e126","journal-title":"Ann Surg"},{"key":"2814_CR58","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.3390\/cancers14184417","volume":"14","author":"LSM Hofste","year":"2022","unstructured":"Hofste LSM, Geerlings MJ, von Rhein D et al (2022) Circulating tumor DNA-based disease monitoring of patients with locally advanced esophageal cancer. Cancers (Basel) 14:4417","journal-title":"Cancers (Basel)"},{"key":"2814_CR59","doi-asserted-by":"publisher","first-page":"e1116","DOI":"10.1002\/ctm2.1116","volume":"12","author":"X Wang","year":"2022","unstructured":"Wang X, Yu N, Cheng G et al (2022) Prognostic value of circulating tumour DNA during post-radiotherapy surveillance in locally advanced esophageal squamous cell carcinoma. Clin Transl Med 12:e1116","journal-title":"Clin Transl Med"},{"key":"2814_CR60","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1001\/jamasurg.2023.4395","volume":"158","author":"HY Ng","year":"2023","unstructured":"Ng HY, Ko J, Lam KO et al (2023) Circulating tumor DNA dynamics as prognostic markers in locally advanced and metastatic esophageal squamous cell carcinoma. JAMA Surg 158:1141\u20131150","journal-title":"JAMA Surg"},{"key":"2814_CR61","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1158\/1538-7445.AM2019-2284","volume":"79","author":"T Iwaya","year":"2019","unstructured":"Iwaya T, Endo F, Sasaki Y et al (2019) Patient-specific circulating tumor DNA monitoring using esophageal squamous cell cancer gene panel and digital PCR. Cancer Res (Chicago Ill) 79:2284","journal-title":"Cancer Res (Chicago Ill)"},{"key":"2814_CR62","doi-asserted-by":"publisher","first-page":"6248","DOI":"10.1158\/1078-0432.CCR-18-1128","volume":"24","author":"S Kato","year":"2018","unstructured":"Kato S, Okamura R, Baumgartner JM et al (2018) Analysis of circulating tumor DNA and clinical correlates in patients with esophageal, gastroesophageal junction, and gastric adenocarcinoma. Clin Cancer Res 24:6248\u20136256","journal-title":"Clin Cancer Res"},{"key":"2814_CR63","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1158\/1538-7445.AM2019-2281","volume":"79","author":"AA Suwaidan","year":"2019","unstructured":"Suwaidan AA, Openshaw MR, Ottolini B et al (2019) Abstract 2281: the role of baseline and early dynamics of ctDNA in predicting response and prognosis of early and advanced gastroesophageal adenocarcinomas. Cancer Res (Chicago Ill) 79:2281","journal-title":"Cancer Res (Chicago Ill)"},{"key":"2814_CR64","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.csbj.2018.05.002","volume":"16","author":"MHD Neumann","year":"2018","unstructured":"Neumann MHD, Bender S, Krahn T, Schlange T (2018) ctDNA and CTCs in liquid biopsy\u2014current status and where we need to progress. Comput Struct Biotechnol J 16:190\u2013195. https:\/\/doi.org\/10.1016\/j.csbj.2018.05.002","journal-title":"Comput Struct Biotechnol J"},{"key":"2814_CR65","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.annonc.2020.12.010","volume":"32","author":"E Ococks","year":"2021","unstructured":"Ococks E, Frankell AM, Masque Soler N, Grehan N, Northrop A, Coles H et al (2021) Longitudinal tracking of 97 esophageal adenocarcinomas using liquid biopsy sampling. Ann Oncol 32:522\u2013532. https:\/\/doi.org\/10.1016\/j.annonc.2020.12.010","journal-title":"Ann Oncol"},{"key":"2814_CR66","doi-asserted-by":"publisher","unstructured":"Openshaw MR, Suwaidan AA, Ottolini B, Fernandez-Garcia D, Richards CJ, Page K et al (20220) Longitudinal monitoring of circulating tumour DNA improves prognostication and relapse detection in gastroesophageal adenocarcinoma. Br J Cancer 123:1271\u20131279. https:\/\/doi.org\/10.1038\/s41416-020-1002-8","DOI":"10.1038\/s41416-020-1002-8"},{"issue":"e4","key":"2814_CR67","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1053\/j.gastro.2020.09.035","volume":"160","author":"T Iwaya","year":"2021","unstructured":"Iwaya T, Endo F, Takahashi F, Tokino T, Sasaki Y, Nishizuka SS (2021) Frequent tumor burden monitoring of esophageal squamous cell carcinoma with circulating tumor DNA using individually designed digital polymerase chain reaction. Gastroenterology 160(e4):463\u2013465. https:\/\/doi.org\/10.1053\/j.gastro.2020.09.035","journal-title":"Gastroenterology"},{"key":"2814_CR68","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1053\/j.gastro.2021.07.011","volume":"161","author":"E Ococks","year":"2021","unstructured":"Ococks E, Sharma S, Ng AWT, Aleshin A, Fitzgerald RC, Smyth E (2021) Serial circulating tumor DNA detection using a personalized, tumor-informed assay in esophageal adenocarcinoma patients following resection. Gastroenterology 161:1705\u20138e2. https:\/\/doi.org\/10.1053\/j.gastro.2021.07.011","journal-title":"Gastroenterology"},{"key":"2814_CR69","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1245\/s10434-023-13194-z","volume":"30","author":"Y Morimoto","year":"2023","unstructured":"Morimoto Y, Matsuda S, Kawakubo H, Nakamura K, Kobayashi R, Hisaoka K, Okui J, Takeuchi M, Aimono E, Fukuda K et al (2023) Tumor burden monitoring with circulating tumor DNA during treatment in patients with esophageal squamous cell carcinoma. Ann Surg Oncol 30:3747\u20133756. https:\/\/doi.org\/10.1245\/s10434-023-13194-z","journal-title":"Ann Surg Oncol"},{"key":"2814_CR70","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41392-021-00817-8","volume":"6","author":"D Lin","year":"2021","unstructured":"Lin D, Shen L, Luo M, Zhang K, Li J, Yang Q, Zhu F, Zhou D, Zheng S, Chen Y et al (2021) Circulating tumor cells: biology and clinical significance. Signal Transduct Target Ther 6:404. https:\/\/doi.org\/10.1038\/s41392-021-00817-8","journal-title":"Signal Transduct Target Ther"},{"key":"2814_CR71","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41392-023-01725-9","volume":"8","author":"Q Zhan","year":"2023","unstructured":"Zhan Q, Liu B, Situ X, Luo Y, Fu T, Wang Y, Xie Z, Ren L, Zhu Y, He W et al (2023) New insights into the correlations between circulating tumor cells and target organ metastasis. Signal Transduct Target Ther 8:465. https:\/\/doi.org\/10.1038\/s41392-023-01725-9","journal-title":"Signal Transduct Target Ther"},{"key":"2814_CR72","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1159\/000478863","volume":"40","author":"J Hoeppner","year":"2017","unstructured":"Hoeppner J, Kulemann B (2017) Circulating tumor cells in esophageal cancer. Oncol Res Treat 40:417\u2013422. https:\/\/doi.org\/10.1159\/000478863","journal-title":"Oncol Res Treat"},{"issue":"16","key":"2814_CR73","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.3390\/cancers16162921","volume":"16","author":"DC Joo","year":"2024","unstructured":"Joo DC, Kim GH, Park IH, Lee SJ, Lee MW BE (2024) Clinical implications of circulating tumor cells in patients with esophageal squamous cell carcinoma: cancer-draining blood versus peripheral blood. Cancers (Basel) 16(16):2921. https:\/\/doi.org\/10.3390\/cancers16162921","journal-title":"Cancers (Basel)"},{"key":"2814_CR74","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s10388-014-0482-0","volume":"12","author":"M Tanaka","year":"2015","unstructured":"Tanaka M, Takeuchi H, Osaki Y, Hiraiwa K, Nakamura R, Oyama T, Takahashi T, Wada N, Kawakubo H, Saikawa Y et al (2015) Prognostic significance of circulating tumor cells in patients with advanced esophageal cancer. Esophagus 12:352\u2013359. https:\/\/doi.org\/10.1007\/s10388-014-0482-0","journal-title":"Esophagus"},{"key":"2814_CR75","doi-asserted-by":"publisher","first-page":"828368","DOI":"10.3389\/fonc.2022.828368","volume":"12","author":"Y Li","year":"2022","unstructured":"Li Y, Wang Z, Fu R, Wang S, Zhang T, Tian X, Yang D (2022) Clinical utility of circulating tumor cells in patients with esophageal cancer. Front Oncol 12:828368. https:\/\/doi.org\/10.3389\/fonc.2022.828368","journal-title":"Front Oncol"},{"issue":"9","key":"2814_CR76","doi-asserted-by":"publisher","first-page":"15815","DOI":"10.18632\/oncotarget.15012","volume":"8","author":"S Wang","year":"2017","unstructured":"Wang S, Du H, Li G (2017) Significant prognostic value of circulating tumor cells in esophageal cancer patients: a meta-analysis. Oncotarget 8(9):15815\u201315826. https:\/\/doi.org\/10.18632\/oncotarget.15012","journal-title":"Oncotarget"},{"issue":"4","key":"2814_CR77","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.21037\/jgo-21-409","volume":"12","author":"Z Ren","year":"2021","unstructured":"Ren Z, Hou X, Xue Z, Zhang L, Wang B, Wen J, Chu X (2021) The relationship between the number of circulating tumor cells and the prognosis in patients with esophageal squamous cell carcinoma. J Gastrointest Oncol 12(4):1265\u20131276. https:\/\/doi.org\/10.21037\/jgo-21-409","journal-title":"J Gastrointest Oncol"},{"issue":"3","key":"2814_CR78","doi-asserted-by":"publisher","first-page":"832","DOI":"10.3390\/cancers15030832","volume":"15","author":"JMY Ko","year":"2023","unstructured":"Ko JMY, Lam KO, Kwong DLW, Wong IY, Chan FS, Wong CL, Chan KK, Law TT, Chiu KWH, Lam CCS, Wong JC, Fong HCH, Choy FSF, Lo A, Law S, Lung ML (2023) Circulating tumor cell enumeration for serial monitoring of treatment outcomes for locally advanced esophageal squamous cell carcinoma. Cancers (Basel) 15(3):832. https:\/\/doi.org\/10.3390\/cancers15030832","journal-title":"Cancers (Basel)"},{"issue":"6","key":"2814_CR79","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1097\/SLA.0000000000001130","volume":"261","author":"M Reeh","year":"2015","unstructured":"Reeh M, Effenberger KE, Koenig AM, Riethdorf S, Eichst\u00e4dt D, Vettorazzi E, Uzunoglu FG, Vashist YK, Izbicki JR, Pantel K, Bockhorn M (2015) Circulating tumor cells as a biomarker for preoperative prognostic staging in patients with esophageal cancer. Ann Surg 261(6):1124\u20131130. https:\/\/doi.org\/10.1097\/SLA.0000000000001130","journal-title":"Ann Surg"},{"key":"2814_CR80","doi-asserted-by":"publisher","first-page":"62754","DOI":"10.18632\/oncotarget.11191","volume":"7","author":"EE van der Toom","year":"2016","unstructured":"van der Toom EE, Verdone JE, Gorin MA, Pienta KJ (2016) Technical challenges in the isolation and analysis of circulating tumor cells. Oncotarget 7:62754\u201362766. https:\/\/doi.org\/10.18632\/oncotarget.11191","journal-title":"Oncotarget"},{"key":"2814_CR81","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ymeth.2010.01.027","volume":"50","author":"M Alunni-Fabbroni","year":"2010","unstructured":"Alunni-Fabbroni M, Sandri MT (2010) Circulating tumour cells in clinical practice: methods of detection and possible characterization. Methods 50:289\u2013297. https:\/\/doi.org\/10.1016\/j.ymeth.2010.01.027","journal-title":"Methods"},{"key":"2814_CR82","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1038\/s41388-024-03076-3","volume":"43","author":"GAD Metcalf","year":"2024","unstructured":"Metcalf GAD (2024) MicroRNAs: circulating biomarkers for the early detection of imperceptible cancers via biosensor and machine-learning advances. Oncogene 43:2135\u20132142. https:\/\/doi.org\/10.1038\/s41388-024-03076-3","journal-title":"Oncogene"},{"key":"2814_CR83","doi-asserted-by":"publisher","first-page":"4051","DOI":"10.1038\/sj.emboj.7600385","volume":"23","author":"Y Lee","year":"2004","unstructured":"Lee Y, Kim M, Han J, Yeom K-H, Lee S, Baek SH, Kim VN (2004) MicroRNA genes are transcribed by RNA polymerase II. EMBO J 23:4051\u20134060. https:\/\/doi.org\/10.1038\/sj.emboj.7600385","journal-title":"EMBO J"},{"key":"2814_CR84","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/ncb1596","volume":"9","author":"H Valadi","year":"2007","unstructured":"Valadi H, Ekstr\u00f6m K, Bossios A, Sj\u00f6strand M, Lee JJ, L\u00f6tvall JO (2007) Exosome-mediated transfer of MRNAs and MicroRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9:654\u2013659. https:\/\/doi.org\/10.1038\/ncb1596","journal-title":"Nat Cell Biol"},{"key":"2814_CR85","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/ncb2210","volume":"13","author":"KC Vickers","year":"2011","unstructured":"Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT (2011) MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 13:423\u2013433. https:\/\/doi.org\/10.1038\/ncb2210","journal-title":"Nat Cell Biol"},{"key":"2814_CR86","doi-asserted-by":"publisher","first-page":"10513","DOI":"10.1073\/pnas.0804549105","volume":"105","author":"PS Mitchell","year":"2008","unstructured":"Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O\u2019Briant KC, Allen A et al (2008) Circulating MicroRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105:10513\u201310518. https:\/\/doi.org\/10.1073\/pnas.0804549105","journal-title":"Proc Natl Acad Sci USA"},{"key":"2814_CR87","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1002\/1878-0261.13026","volume":"15","author":"N Laprovitera","year":"2021","unstructured":"Laprovitera N, Riefolo M, Porcellini E, Durante G, Garajova I, Vasuri F, Aigelsreiter A, Dandachi N, Benvenuto G, Agostinis F et al (2021) MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary. Mol Oncol 15:2732\u20132751. https:\/\/doi.org\/10.1002\/1878-0261.13026","journal-title":"Mol Oncol"},{"issue":"1","key":"2814_CR88","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12943-022-01507-x","volume":"21","author":"J Miyoshi","year":"2022","unstructured":"Miyoshi J, Zhu Z, Luo A, Toden S, Zhou X, Izumi D, Kanda M, Takayama T, Parker IM, Wang M, Gao F, Zaidi AH, Baba H, Kodera Y, Cui Y, Wang X, Liu Z, Goel A (2022) A microRNA-based liquid biopsy signature for the early detection of esophageal squamous cell carcinoma: a retrospective, prospective and multicenter study. Mol Cancer 21(1):44. https:\/\/doi.org\/10.1186\/s12943-022-01507-x","journal-title":"Mol Cancer"},{"issue":"10","key":"2814_CR89","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1158\/1078-0432.CCR-16-1676","volume":"23","author":"K Shigeyasu","year":"2017","unstructured":"Shigeyasu K, Toden S, Zumwalt TJ, Okugawa Y, Goel A (2017) Emerging role of MicroRNAs as liquid biopsy biomarkers in gastrointestinal cancers. Clin Cancer Res 23(10):2391\u20132399. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1676","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2814_CR90","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.3390\/cancers12103070","volume":"12","author":"D Matsushita","year":"2020","unstructured":"Matsushita D, Arigami T, Okubo K, Sasaki K, Noda M, Kita Y, Mori S, Uenosono Y, Ohtsuka T, Natsugoe S (2020) The diagnostic and prognostic value of a liquid biopsy for esophageal cancer: a systematic review and meta-analysis. Cancers (Basel) 12(10):3070. https:\/\/doi.org\/10.3390\/cancers12103070","journal-title":"Cancers (Basel)"},{"key":"2814_CR91","doi-asserted-by":"publisher","first-page":"1642705","DOI":"10.3389\/fonc.2025.1642705","volume":"15","author":"MK Maxwell","year":"2026","unstructured":"Maxwell MK, Nonaka T (2026) Saliva and blood miRNAs as complementary biomarkers for esophageal cancer detection. Front Oncol 15:1642705. https:\/\/doi.org\/10.3389\/fonc.2025.1642705","journal-title":"Front Oncol"},{"issue":"2","key":"2814_CR92","doi-asserted-by":"publisher","first-page":"878","DOI":"10.3390\/ijms27020878","volume":"27","author":"E Cataldi-Stagetti","year":"2026","unstructured":"Cataldi-Stagetti E, Governatori G, Orsini A, De Nicolo B, Zagari RM, Bonora E (2026) MicroRNAs in esophageal cancer: implications for diagnosis, progression, prognosis and chemoresistance. Int J Mol Sci 27(2):878. https:\/\/doi.org\/10.3390\/ijms27020878","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2814_CR93","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.3390\/cancers16091698","volume":"16","author":"K Hisaoka","year":"2024","unstructured":"Hisaoka K, Matsuda S, Minoura K, Yamaguchi H, Ichikawa Y, Mizunuma M, Kobayashi R, Morimoto Y, Takeuchi M, Fukuda K, Nakamura R, Hori S, Yamazaki T, Sambe T, Kawakubo H, Kitagawa Y (2024) Identifying the trends of urinary microRNAs within extracellular vesicles for esophageal cancer. Cancers (Basel) 16(9):1698. https:\/\/doi.org\/10.3390\/cancers16091698","journal-title":"Cancers (Basel)"},{"key":"2814_CR94","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1053\/j.gastro.2023.06.021","volume":"165","author":"K Li","year":"2023","unstructured":"Li K, Lin Y, Zhou Y, Xiong X, Wang L, Li J, Zhou F, Guo Y, Chen S, Chen Y et al (2023) Salivary extracellular MicroRNAs for early detection and prognostication of esophageal cancer: a clinical study. Gastroenterology 165:932\u2013945e9. https:\/\/doi.org\/10.1053\/j.gastro.2023.06.021","journal-title":"Gastroenterology"},{"key":"2814_CR95","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12943-022-01525-9","volume":"21","author":"KA Preethi","year":"2022","unstructured":"Preethi KA, Selvakumar SC, Ross K, Jayaraman S, Tusubira D, Sekar D (2022) Liquid biopsy: exosomal MicroRNAs as novel diagnostic and prognostic biomarkers in cancer. Mol Cancer 21:54. https:\/\/doi.org\/10.1186\/s12943-022-01525-9","journal-title":"Mol Cancer"},{"key":"2814_CR96","doi-asserted-by":"publisher","unstructured":"Richter F, Henssen C, Steiert TA, Meissner T, Mehdorn AS, R\u00f6cken C, Franke A, Egberts JH, Becker T, Sebens S, Forster M (2023) Combining solid and liquid biopsy for therapy monitoring in esophageal cancer. Int J Mol Sci 24(13):10673. https:\/\/doi.org\/10.3390\/ijms241310673","DOI":"10.3390\/ijms241310673"},{"key":"2814_CR97","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.3389\/fonc.2020.01320","volume":"10","author":"E Boldrin","year":"2020","unstructured":"Boldrin E, Curtarello M, Fassan M, Rugge M, Realdon S, Alfieri R, Amadori A, Saggioro D (2020) Allelic imbalance analysis in liquid biopsy to monitor locally advanced esophageal cancer patients during treatment. Front Oncol 10:1320. https:\/\/doi.org\/10.3389\/fonc.2020.01320","journal-title":"Front Oncol"},{"issue":"1","key":"2814_CR98","doi-asserted-by":"publisher","first-page":"e005924","DOI":"10.1136\/jitc-2022-005924","volume":"11","author":"L Sivapalan","year":"2023","unstructured":"Sivapalan L, Murray JC, Canzoniero JV, Landon B, Jackson J, Scott S, Lam V, Levy BP, Sausen M, Anagnostou V (2023) Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy. J Immunother Cancer 11(1):e005924. https:\/\/doi.org\/10.1136\/jitc-2022-005924","journal-title":"J Immunother Cancer"},{"key":"2814_CR99","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature22364","volume":"545","author":"C Abbosh","year":"2017","unstructured":"Abbosh C, Birkbak N, Wilson G et al (2017) Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 545:446\u2013451. https:\/\/doi.org\/10.1038\/nature22364","journal-title":"Nature"},{"issue":"1","key":"2814_CR100","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41698-024-00544-7","volume":"8","author":"D Vasseur","year":"2024","unstructured":"Vasseur D, Arbab A, Giudici F, Marzac C, Michiels S, Tagliamento M, Bayle A, Smolenschi C, Sakkal M, Aldea M, Sassi H, Dall\u2019Olio FG, Pata-Merci N, Cotteret S, Fi\u00e9vet A, Auger N, Friboulet L, Facchinetti F, G\u00e9raud A, Ponce S, Hollebecque A, Besse B, Micol JB, Italiano A, Lacroix L, Rouleau E (2024) Genomic landscape of liquid biopsy mutations in TP53 and DNA damage genes in cancer patients. NPJ Precis Oncol 8(1):51. https:\/\/doi.org\/10.1038\/s41698-024-00544-7","journal-title":"NPJ Precis Oncol"},{"issue":"19","key":"2814_CR101","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.3390\/cancers17193165","volume":"17","author":"SP Cherukuri","year":"2025","unstructured":"Cherukuri SP, Kaur A, Goyal B, Kukunoor HR, Sahito AF, Sachdeva P, Yerrapragada G, Elangovan P, Shariff MN, Natarajan T, Janarthanan J, Richard S, Pallikaranai Venkatesaprasath S, Karuppiah SS, Iyer VN, Helgeson SA, Arunachalam SP (2025) Artificial intelligence-enhanced liquid biopsy and radiomics in early-stage lung cancer detection: a precision oncology paradigm. Cancers (Basel) 17(19):3165. https:\/\/doi.org\/10.3390\/cancers17193165","journal-title":"Cancers (Basel)"},{"key":"2814_CR102","doi-asserted-by":"publisher","first-page":"100008","DOI":"10.1016\/j.jlb.2023.100008","volume":"1","author":"A Abad","year":"2023","unstructured":"Abad A, Vidal J, Layos L, Morcillo C, Achaerandio I, Viteri S (2023) Liquid biopsy, big data and artificial intelligence as a new global clinical trial model in targeted therapy. J Liq Biopsy 1:100008. https:\/\/doi.org\/10.1016\/j.jlb.2023.100008","journal-title":"J Liq Biopsy"},{"key":"2814_CR103","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.gie.2015.11.026","volume":"83","author":"PSN van Rossum","year":"2016","unstructured":"van Rossum PSN, Goense L, Meziani J, Reitsma JB, Siersema PD, Vleggaar FP, van Vulpen M, Meijer GJ, Ruurda JP, van Hillegersberg R (2016) Endoscopic biopsy and EUS for the detection of pathologic complete response after neoadjuvant chemoradiotherapy in esophageal cancer: a systematic review and meta-analysis. Gastrointest Endosc 83:866\u2013879. https:\/\/doi.org\/10.1016\/j.gie.2015.11.026","journal-title":"Gastrointest Endosc"},{"key":"2814_CR104","doi-asserted-by":"publisher","first-page":"5159","DOI":"10.21037\/jtd.2019.08.15","volume":"12","author":"SB Elsherif","year":"2020","unstructured":"Elsherif SB, Andreou S, Virarkar M, Soule E, Gopireddy DR, Bhosale PR, Lall C (2020) Role of precision imaging in esophageal cancer. J Thorac Dis 12:5159\u20135176. https:\/\/doi.org\/10.21037\/jtd.2019.08.15","journal-title":"J Thorac Dis"},{"key":"2814_CR105","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.molmed.2010.07.001","volume":"16","author":"K Pantel","year":"2010","unstructured":"Pantel K, Alix-Panabi\u00e8res C (2010) Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med 16:398\u2013406. https:\/\/doi.org\/10.1016\/j.molmed.2010.07.001","journal-title":"Trends Mol Med"},{"issue":"1","key":"2814_CR106","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00423-026-04050-1","volume":"411","author":"A Aiolfi","year":"2026","unstructured":"Aiolfi A, Wang Q, Mascagni P, Bona D, Leone N, Bonavina L (2026) Artificial intelligence for surgical management of benign esophageal disease: scoping review and evidence mapping. Langenbecks Arch Surg 411(1):149. https:\/\/doi.org\/10.1007\/s00423-026-04050-1","journal-title":"Langenbecks Arch Surg"}],"container-title":["Updates in Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13304-026-02814-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13304-026-02814-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13304-026-02814-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:55:44Z","timestamp":1787579744000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13304-026-02814-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":106,"alternative-id":["2814"],"URL":"https:\/\/doi.org\/10.1007\/s13304-026-02814-4","relation":{},"ISSN":["2038-131X","2038-3312"],"issn-type":[{"value":"2038-131X","type":"print"},{"value":"2038-3312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"assertion":[{"value":"1 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"<b>Conflict of interest<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","label":"<b>Ethical approval and consent to participate<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors approved the publication of the manuscript in the Journal.","order":3,"name":"Ethics","label":"<b>Consent for publication<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}}]}}